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Abstract
Background
Systemic corticosteroids have anti-inflammatory effects, whereas macrolides also have
immunomodulatory activity in addition to their primary antimicrobial actions. We aimed to
evaluate the potential interaction effect between corticosteroids and macrolides on the sys-
temic inflammatory response in patients with severe community-acquired pneumonia to
determine if combining these two immunomodulating agents was harmful, or possibly
beneficial.
Methods
We performed a post-hoc exploratory analysis of a randomized clinical trial conducted in
three tertiary hospitals in Spain. This trial included patients with severe community-acquired
pneumonia with high inflammatory response (C-reactive protein [CRP] >15 mg/dL) who
were randomized to receive methylprednisolone 0.5 mg/kg/tpd or placebo. The choice of
antibiotic treatment was at the physician’s discretion. One hundred and six patients were
classified into four groups according to antimicrobial therapy combination (β-lactam plus
macrolide or β-lactam plus fluoroquinolone) and corticosteroid arm (placebo or corticoste-
roids). The primary outcome was treatment failure (composite outcome of early treatment
failure, or of late treatment failure, or of both early and late treatment failure).
PLOS ONE | https://doi.org/10.1371/journal.pone.0178022 June 15, 2017 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Ceccato A, Cilloniz C, Ranzani OT,
Menendez R, Agusti C, Gabarrus A, et al. (2017)
Treatment with macrolides and
glucocorticosteroids in severe community-
acquired pneumonia: A post-hoc exploratory
analysis of a randomized controlled trial. PLoS ONE
12(6): e0178022. https://doi.org/10.1371/journal.
pone.0178022
Editor: Pedro Po´voa, Hospital Sao Francisco
Xavier, PORTUGAL
Received: December 22, 2016
Accepted: May 5, 2017
Published: June 15, 2017
Copyright: © 2017 Ceccato et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by Instituto de
Salud Carlos III (Fis PI15/00506). Adrian Ceccato
and Otavio T Ranzani are recipients of an ERS long
term fellowship. Catia Cilloniz is recipient of an ERS
short term fellowship. All funders had no role in
Results
The methylprednisolone with β-lactam plus macrolide group had more elderly patients, with
comorbidities, and higher pneumonia severity index (PSI) risk class V, but a lower proportion
of intensive care unit admission, compared to the other groups. We found non differences in
treatment failure between groups (overall p = 0.374); however, a significant difference in late
treatment failure was observed (4 patients in the placebo with β-lactam plus macrolide group
(31%) vs. 9 patients in the placebo with β-lactam plus fluoroquinolone group (24%) vs. 0
patients in the methylprednisolone with β-lactam plus macrolide group (0%) vs. 2 patients
[5%] in the methylprednisolone with β-lactam plus fluoroquinolone group overall p = 0.009).
We found a significant difference for In-hospital mortality in the per protocol population (over-
all p = 0.01). We did not find significant differences in treatment failure, early or late; or In-hos-
pital mortality after adjusting for severity (PSI), year and centre of enrolment.
Conclusions
In this exploratory analysis, we observed that the glucocorticosteroids and macrolides com-
bination had no statistically significant association with main clinical outcomes compared
with other combinations in patients with severe community acquired pneumonia and a high
inflammatory response after taking account potential confounders.
Trial registration
Clinicaltrials.gov NCT00908713.
Background
Despite advances in antibiotic treatment, the mortality of hospitalized community-acquired
pneumonia (CAP) patients is still high, especially in those with severe illness[1,2]. In severe
CAP, high levels of inflammatory cytokines can be harmful and cause pulmonary dysfunction
associated with adverse outcomes[3,4]. On the other hand, a reduced inflammatory reaction,
as seen in immunosuppressed patients or elderly can be dangerous and lead to worse out-
comes[5–7]. Several treatments have been tested to control the dysregulated inflammatory
response in CAP [8,9], however it is still not clear which therapies could best achieve these
goals, leading to improved outcomes or which could worsen the condition.
The mortality of patients with severe CAP can be high regardless of whether they receive
adequate and prompt antibiotic treatment. Macrolide combination therapy was associated
with reduced mortality in retrospective analyses and in non-interventional studies, mainly in
patients with severe pneumonia[10,11]. The use of systemic corticosteroids in addition to the
antibiotic treatment in CAP seems to have beneficial effects, mainly for severe CAP[12–16].
Systemic corticosteroids have anti-inflammatory effects and macrolides also have immuno-
modulatory activity in addition to their primary antimicrobial actions. Macrolides are concen-
trated in phagocytic cells and dampen the inflammatory response by inhibiting the generation
of proinflammatory cytokines[17]. They have been used in low doses for long-term therapy in
asthma[18], chronic obstructive pulmonary disease[19], cystic fibrosis[20] and bronchiectasis
[21] because of these anti-inflammatory actions.
There is a gap in knowledge about whether the potential anti-inflammatory effect of corti-
costeroids could be potentiated by the administration of a macrolide. The combination of
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macrolide plus corticosteroids is currently used without a scientific evaluation, although we do
not know whether this combination could decrease the inflammatory response to a very low
level, increasing the risk of side effects.
We hypothesized that when macrolides are used with adjunctive glucocorticosteroid treat-
ment, there would be a better modulation of the inflammatory response without greater risk of
side effects, than with either agent alone, which could, in turn, lead to a lower rate of treatment
failure.
Methods
We conducted an exploratory post-hoc analysis of data from a multicentre, randomized,
double-blind, placebo-controlled trial (Clinicaltrials.gov Identifier: NCT00908713) involving
patients with both severe CAP and a high inflammatory response, defined by a level of C-re-
active protein (CRP) >15 mg/dL on admission, as described in detail elsewhere[12]. We
included 106 patients with severe CAP and a high inflammatory response, who received pla-
cebo or glucocorticosteroids and antibiotic therapy with a β-lactam plus macrolide or β-lactam
plus fluoroquinolone. Fourteen patients who received antibiotic monotherapy were excluded
from the analysis since this is not the recommended empiric antibiotic treatment for severe
pneumonia. Patients with influenza infection were also excluded from the original trial.
Patients were recruited from the Departments of Pneumology of three tertiary Spanish hos-
pitals. The local ethic committee ¨Comite´ E´tico de Investigacio´n Clı´nica del Hospital Clinic de
Barcelona¨ approved the study protocol and written informed consent was obtained from all
participants or from their authorized representatives.
Antimicrobial treatment
All patients were treated with antibiotics according to current international guidelines[22]. All
patients in this analysis received a β-lactam plus a macrolide or a fluoroquinolone. Switch
from intravenous to oral therapy and duration of the antibiotic treatment was entirely left to
the discretion of the medical team, as was the decision to transfer patients to the intensive care
unit or for hospital discharge.
Data collection
The following data were collected on admission: age, gender, smoking history, clinical symp-
toms, physical examination and comorbidities. The initial risk class was calculated using a
pneumonia severity index (PSI) score[23] and severity criteria were assessed according to the
ATS criteria modified by Ewig et al[24]. Patients were evaluated daily for treatment failure and
time to clinical stability until discharge day [25]. Adverse events and mortality were recorded
during the hospital stay.
Microbiologic examination methods are described elsewhere [12].
Biormarker measurements
Samples for cytokine, procalcitonin and C-reactive protein (CRP) determinations were
obtained on the first day and after 72h and 7 days of treatment, centrifuged and frozen at
-80˚C until analysis. Determination of interleukin (IL)- 6, IL-8 and IL-10 levels was performed
using a commercial enzyme immunoassay technique (Biosource, Nivelles, Belgium). An
immunoluminometric technique was used to measure procalcitonin (Liaison Brahms PCT;
DiaSorin, Saluggia, Italy) with a detection limit of 0.3 ng/ml. CRP was measured with an
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immunoturbidimetric method using a commercially available test (Bayer Diagnostics, Lever-
kusen, Germany) with an Advia 2400.
Outcomes
The primary outcome was the rate of treatment failure, which includes treatment failure that
occurred early, late, or at both times. Secondary outcomes were the levels in inflammatory
markers (IL-6, IL-8, IL-10, procalcitonin, and CRP) after 3 days of treatment, time to clinical
stability, length of intensive care unit (ICU) and hospital stay, and in-hospital mortality. Early
treatment failure was defined as clinical deterioration within 72 hours of treatment (including
development of shock, need for invasive mechanical ventilation not present at baseline, or
death). Late treatment failure was defined as radiographic progression, persistence of severe
respiratory failure, development of shock, need for invasive mechanical ventilation not present
at baseline, or death between 72 hours and 120 hours after treatment initiation.
Statistical analysis
Efficacy data were analyzed for both the intention-to-treat and the per-protocol populations.
The intention-to-treat population included all randomized patients who received at least one
dose of the study drug. The per-protocol population included all randomized patients who
met all inclusion criteria, received at least six doses of the study drug, and did not deviate sub-
stantially from the protocol.
We report the number and percentage of patients for categorical variables, the mean (stan-
dard deviation) and median (interquartile range) for continuous variables. Categorical vari-
ables were compared using the χ2 test or the Fisher exact test. Continuous variables were
compared using nonparametric Kruskal-Wallis test. Pairwise comparisons were carried out
via the Bonferroni method in order to control for the experiment-wise error rate. We also per-
formed logistic regression models to examine differences in the rate of treatment failure, early
and late treatment failure and in-hospital mortality between groups, adjusting for the PSI risk
class, year of recruitment, and centre. Time to clinical stability and length of ICU and hospital
stay in the groups were analyzed by means of Cox proportional hazards models, adjusting for
the PSI risk class, year of recruitment, and centre. The odds ratio (OR) or hazard ratio (HR)
and their 95% confidence intervals (CI) were estimated. We fitted analysis of covariance
(ANCOVA) models to analyze the inflammatory response at day 3, adjusting for the baseline
inflammatory marker value, PSI risk class, year of recruitment, and centre. Inflammatory
markers were log-transformed to fit the ANCOVA model. Each treatment effect was estimated
by the least squares mean and its 95% CI. We conducted a sensitivity analysis adjusting the
previous multivariate models for age, ICU admission, year and centre of enrolment. The qual-
ity of the logistic regression models and ANCOVA models were tested using the Hosmer-
Lemeshow test and Akaike information criterion, respectively. All tests were 2-tailed and sig-
nificance was set at 0.05. All analyses were performed with IBM SPSS Statistics version 22.0
(Armonk, New York, USA).
Results
Of the 106 patients, 28 received combination therapy consisting of a β-lactam plus macrolide
(13 [12%] in the placebo group and 15 [14%] in the methylprednisolone group) and 78
received the combination of a β-lactam plus fluoroquinolone (37 [35%] in the placebo group
and 41 [39%] in the methylprednisolone group) ¨Fig 1¨. The baseline characteristics are pre-
sented in Table 1. The methylprednisolone with β-lactam plus macrolide group had more
elderly patients, with comorbidities, and higher PSI risk class V, but a lower proportion of ICU
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admission, compared to the other groups. The rate of etiologic diagnosis was higher in the
methylprednisolone with β-lactam plus fluoroquinolone group. Streptococcus pneumoniae was
the most common etiologic agent in the four groups (Table 2). Distribution of the pathogens
did not differ among groups, except for polymicrobial infection (24% in the methylpredniso-
lone with β-lactam plus fluoroquinolone group vs. 0% in the methylprednisone with β-lactam
plus macrolide group [p = 0.018]).
The most common antimicrobial treatment used was ceftriaxone plus levofloxacin in 33
[31%] patients in the group of placebo and 37 [34%] in the methylprednisolone group), ceftri-
axone plus azithromycin was used in 11 (10%) patients of placebo group and 13 (12%) patients
in the methylprednisolone group. More data about antimicrobial treatment, duration and
time to the first dose are described elsewhere[12].
Treatment failure did not differ among the four groups (Table 3), nor did early treatment
failure. However, late treatment failure did differ among the four groups (4 patients in the pla-
cebo with β-lactam plus macrolide group (31%) vs. 9 patients in the placebo with β-lactam plus
fluoroquinolone group (24%) vs. 0 patients in the methylprednisolone with β-lactam plus
macrolide group (0%) vs. 2 patients [5%] in the methylprednisolone with β-lactam plus fluoro-
quinolone group, overall crude comparison: p = 0.009). Similar results were obtained in the
per-protocol population. Despite no statistically significant differences between groups were
observed for in-hospital mortality in the intention-to-treat population, these differences were
statistically significant in the per-protocol population (3 patients in the placebo with β-lactam
plus macrolide group [23%] vs. 1 patients in the placebo with β-lactam plus fluoroquinolone
Fig 1. Flow diagram of the study.
https://doi.org/10.1371/journal.pone.0178022.g001
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group [3%] vs. 2 patients in the methylprednisolone with β-lactam plus macrolide group [14%]
vs. 0 patients in the methylprednisolone with β-lactam plus fluoroquinolone group [0%], overall
crude comparison p = 0.010). We did not find significant differences in treatment failure, early
or late; or In-hospital mortality after adjusting for severity (PSI), year and centre of enrolmentin
either the intention-to-treat population (Table 4) or the per-protocol population.
Table 1. Baseline characteristics.
Variable Placebo with β-
lactams plus
Macrolides Group
(n = 13)
Placebo with β-lactams
plus Fluoroquinolones
Group (n = 37)
Methylprednisolone with β-
lactams plus Macrolides
Group (n = 15)
Methylprednisolone with β-
lactams plus Fluoroquinolones
Group (n = 41)
P
value*
Age, years <0.001
Mean (SD) 71.1 (16.9) 60.5 (20.9) 78.5 (10.7) 57.2 (18.5)
Median (IQR) 77.0 (59.0; 85.0) 63.0 (44.0; 77.0)c 82.0 (78.0; 84.0)b,d 58.0 (45.0; 74.0)c
Male sex, No. (%) 10 (77) 22 (59) 8 (53) 23 (56) 0.558
Current smoker,
No. (%)
3 (23) 13 (35) 0 (0) 14 (34) 0.056
Pre-existing
comorbid
conditions, No.
(%)e
Diabetes mellitus 3 (23) 9 (24) 5 (33) 3 (7) 0.090
Chronic
pulmonary
disease
2 (15) 7 (19) 2 (13) 5 (12) 0.867
Congestive heart
failure
4 (31) 15 (41) 11 (73)d 10 (24)c 0.009
History of
malignancy
2 (15) 5 (14) 1 (7) 0 (0) 0.094
Ischemic heart
disease
3 (23) 4 (11)c 7 (47)b,d 4 (10)c 0.007
Pneumonia
Severity Index
score
<0.001
Mean (SD) 131.0 (21.7) 97.8 (34.0) 133.5 (35.5) 91.1 (30.1)
Median (IQR) 132.5 (112.5; 144.5)
b,d
104.0 (75.5; 123.5)a,c 134.0 (130.0; 149.0)b,d 94.5 (75.0; 112.5)a,c
Risk class, No.
(%)f
<0.001
I-III 0 (0)d 13 (35)c 1 (7)b 17 (41)a 0.006
IV 7 (54) 17 (46) 3 (20) 18 (44) 0.265
V 6 (46) 7 (19)c 11 (73)b,d 6 (15)c <0.001
ICU admission,
No. (%)
7 (54)b,d 35 (95)a,c 6 (40)b,d 37 (90)a,c <0.001
Abbreviations: ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
* P values were calculated either by the χ2 test or the Kruskal-Wallis test.
a P<0.05 vs. placebo with β-lactam plus macrolide group.
b P<0.05 vs. placebo with β-lactam plus fluoroquinolone group.
c P<0.05 vs. methylprednisolone with β-lactam plus macrolide group.
d P<0.05 vs. methylprednisolone with β-lactam plus fluoroquinolone group.
e Patients could have more than one comorbidity.
f Pneumonia severity index stratifies patients with CAP according to 30 day risk mortality of CAP in 5 different classes: risk classes from 1–3 (90 points)
have a low mortality and risk classes 4 (91–130 points) and 5 (>130 points) have the highest mortality.
https://doi.org/10.1371/journal.pone.0178022.t001
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Results of statistical analyses of the inflammatory response at day 3, adjusting for the base-
line inflammatory marker value, PSI risk class, year of recruitment, and centre of enrolment
based on the ANCOVA models showed a significant effect of corticosteroids for IL-6, procalci-
tonin, and IL-8 (p<0.001, p = 0.016 and p = 0.028, respectively) (Table 5). For the interaction
between glucocorticosteroids and antibiotics for procalcitonin a trend towards statistical sig-
nificance was observed, mainly driven by lower values in the methylprednisolone with β-lac-
tam plus macrolide group after adjustments for potential confounders. For IL-8, we observed
lower values in the methylprednisolone with β-lactam plus macrolide group, although the
interaction was not significant. Similar results were obtained in the per-protocol population.
Analyses of primary and secondary outcomes, adjusting for age and ICU admission,
showed no significance differences between groups (Tables B and C in S1 Supplementary file).
The results of the methods for assessing the quality of the models are shown in Table D in S1
Supplementary file. Comparing only patients who received methylprednisolone with a β-lac-
tam plus macrolide with the overall population, we did not observe significant differences
(Tables E and F in S1 Supplementary file).
Discussion
In this post-hoc exploratory analysis, we observed that patients who received glucocorticoster-
oids combined with macrolides did not have worse outcomes than those patients who received
other combinations. Thus it does not appear to be unsafe to combine a macrolide with gluco-
corticosteroids when treating CAP, even though both have immune modulating effects. Fur-
thermore, we observed a lower rate of late treatment failure and a trend of interaction for
improved trend in biomarker findings, when using both glucocorticosteroids and macrolides,
as reflected by procalcitonin at day 3.
Severe pneumonia patients have shown increased serum levels of IL-6, IL-8 and IL-10, and
the excess of IL-6 and IL-10 are associated with an increase in mortality from 4.8% to 11.4%
Table 2. Microbiologic identification for the intention-to-treat population.
Placebo with β-
lactams plus
Macrolides Group
(n = 13)
Placebo with β-lactams
plus Fluoroquinolones
Group
(n = 37)
Methylprednisolone with β-
lactams plus Macrolides
Group
(n = 15)
Methylprednisolone with β-
lactams plus Fluoroquinolones
Group
(n = 41)
P
value*
Microorganism 0.477
Streptococcus
pneumoniae
2(15) 7(19) 3(20) 7(17) 0.986
Legionella
pneumophila
0 (0) 1 (3) 1 (7) 2 (5) 0.777
Gram-negative
bacteria
0 (0) 1 (3) 0 (0) 0 (0) 0.601
Staphylococcus
aureus
0 (0) 0 (0) 0 (0) 1 (2) 0.663
Coxiellaburnetti 0 (0) 0 (0) 0 (0) 1 (2) 0.663
Respiratory virus 0 (0) 1 (3) 1 (7) 3 (7) 0.636
Polymicrobial 0 (0) 3 (8) 0 (0) 10 (24) 0.018
Unknown etiology 11 (85)b 24 (65) 10 (67) 17 (41)a 0.022
Data are shown as number of patients (%).
* P values were calculated by the χ2 test.
a P<0.05 vs. placebo with β-lactams plus macrolides group.
b P<0.05 vs. methylprednisolone with β-lactams plus fluoroquinolones group.
https://doi.org/10.1371/journal.pone.0178022.t002
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Table 3. Outcomes using descriptive statistics for the intention-to- treat population.
Placebo with β-
lactams plus
Macrolides Group
(n = 13)
Placebo with β-lactams
plus Fluoroquinolones
Group (n = 37)
Methylprednisolone with β-
lactams plus Macrolides
Group (n = 15)
Methylprednisolone with β-
lactams plus Fluoroquinolones
Group (n = 41)
P
value*
Primary Outcomes
Treatment failure,
No. (%)d
4 (31) 10 (27) 2 (13) 6 (15) 0.374
Early treatment
failure (0–72 h), No.
(%)e
0 (0) 3 (8) 2 (13) 4 (10) 0.626
Early mechanical
ventilation, No. (%)
0 (0) 3 (8) 1 (7) 3 (7) 0.780
Early septic shock,
No. (%)
0 (0) 0 (0) 2 (13) 0 (0) 0.006
Death within 0–72
h, No. (%)
0 (0) 1 (3) 1 (7) 1 (2) 0.751
Late treatment
failure (72–120 h),
No. (%)e
4 (31) 9 (24) 0 (0) 2 (5) 0.009
Radiographic
progression, No.
(%)
2 (15) 5 (14) 0 (0) 1 (2) 0.122
Respiratory failure,
No. (%)
2 (15) 2 (5) 0 (0) 1 (2) 0.208
Late mechanical
ventilation, No. (%)
2 (15) 1 (3) 0 (0) 1 (2) 0.125
Late septic shock,
No. (%)
1 (8) 3 (8) 0 (0) 0 (0) 0.198
Death within 72–
120 h, No. (%)
0 (0) 0 (0) 0 (0) 0 (0) -
Secondary
Outcomes
C-reactive protein,
mg/L
Day 1 (n = 98) 0.062
Mean (SD) 230 (80) 231 (67) 191 (95) 255 (84)
Median (IQR) 244 (165; 294) 250 (182; 284) 238 (194; 244) 282 (204; 301)
Day 3 (n = 88) 0.023
Mean (SD) 170 (97) 158 (80) 98 (67) 113 (66)
Median (IQR) 190 (96; 241) 145 (102; 238) 105 (48; 119) 102 (67; 146)
Procalcitonin, ng/
dL
Day 1 (n = 97) 0.032
Mean (SD) 6.8 (8.4) 6.3 (7.6) 2.4 (4.2) 4.8 (10.4)
Median (IQR) 1.5 (0.5; 15.9) 4.2 (1.0; 8.4) 0.5 (0.1; 2.1) 1.3 (0.4; 4.1)
Day 3 (n = 88) 0.011
Mean (SD) 4.2 (3.9) 3.1 (6.0) 0.9 (1.6) 1.6 (2.9)
Median (IQR) 3.7 (0.4; 7.5) 1.0 (0.4; 2.9) 0.2 (0.1; 1.1) 0.5 (0.2; 1.7)
Interleukin-6, pg/dL
Day 1 (n = 95) 0.262
Mean (SD) 1042 (1367) 1165 (2588) 361 (446) 924 (2813)
Median (IQR) 197 (169; 1534) 337 (219; 754) 165 (137; 243) 347 (134; 715)
(Continued)
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Table 3. (Continued)
Placebo with β-
lactams plus
Macrolides Group
(n = 13)
Placebo with β-lactams
plus Fluoroquinolones
Group (n = 37)
Methylprednisolone with β-
lactams plus Macrolides
Group (n = 15)
Methylprednisolone with β-
lactams plus Fluoroquinolones
Group (n = 41)
P
value*
Day 3 (n = 76) <0.001
Mean (SD) 250 (385) 278 (488) 70 (66) 103 (196)
Median (IQR) 130 (102; 212)c 173 (109; 250)c 44 (14; 134) 49 (31; 67)a,b
Interleukin-8, pg/dL
Day 1 (n = 88) 0.405
Mean (SD) 141 (117) 4728 (24082) 102 (180) 249 (564)
Median (IQR) 99 (57; 182) 76.5 (42; 151) 41 (36; 83) 80 (34.5; 161)
Day 3 (n = 78) 0.206
Mean (SD) 203 (390) 134 (150) 47 (56) 139 (205)
Median (IQR) 100 (36.5; 160) 67.5 (32; 194.5) 21.5 (17; 58) 53.5 (24.5; 149)
Interleukin-10, pg/
dL
Day 1 (n = 95) 0.075
Mean (SD) 11.5 (11.3) 23.9 (55.8) 5.5 (7.2) 25.9 (85.6)
Median (IQR) 7.8 (6.8; 11.5) 6.4 (3.5; 14.0) 4.1 (2.4; 4.8) 6.2 (2.9; 10.0)
Day 3 (n = 84) 0.019
Mean (SD) 9.6 (11.7) 9.5 (11.8) 5.5 (8.9) 17.1 (77.7)
Median (IQR) 6.9 (2.5; 10.0) 4.6 (2.7; 11.0) 4.0 (1.2; 4.6) 3.1 (1.1; 5.5)
Time to clinical
stability, daysf
0.193
Mean (SD) 5.3 (4.2) 6.9 (5.7) 3.8 (1.9) 5.9 (4.8)
Median (IQR) 4.0 (3.0; 6.0) 5.5 (3.5; 8.0) 4.0 (3.0; 4.0) 4.5 (3.0; 7.0)
Length of hospital
stay, days
0.920
Mean (SD) 12.9 (7.3) 16.4 (21.4) 12.4 (5.7) 15.9 (17.3)
Median (IQR) 10.0 (8.0; 16.0) 12.0 (9.0; 15.0) 13.0 (8.0; 15.0) 11.0 (8.0; 14.5)
Length of ICU stay,
daysg
0.833
Mean (SD) 7.0 (3.4) 7.9 (9.7) 5.8 (4.5) 8.6 (11.4)
Median (IQR) 7.0 (4.0; 10.0) 6.0 (4.0; 8.0) 4.5 (4.0; 7.0) 5.0 (3.0; 8.0)
In-hospital
mortality, No. (%)
3 (23) 2 (5) 3 (20) 2 (5) 0.090
Abbreviations: ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
* P values were calculated either by the χ2 test or the Kruskal-Wallis test.
a P<0.05 vs. placebo with β-lactams plus macrolides group.
b P<0.05 vs. placebo with β-lactams plus fluoroquinolones group.
c P<0.05 vs. methylprednisolone with β-lactams plus fluoroquinolones group.
d Defined as the presence of early, late failure or both.
e Several patients had more than 1 criteria of failure.
f Clinical stability was considered to be attained when the following values were achieved for all parameters: temperature of 37.2˚C or lower; heart rate of
100 beats/min or lower; systolic blood pressure of 90 mmHg or higher; and arterial oxygen tension of 60 mmHg or higher when the patient was not receiving
supplemental oxygen. In patients who were receiving home oxygen therapy, stability was considered to be achieved when their oxygen needs were the
same as before admission.
g There were 7 patients in the placebo with β-lactam plus macrolide group, 34 patients in the placebo with β-lactams plus fluoroquinolones group, 6 patients
in the methylprednisolone with β-lactams plus macrolides group, and 36 patients in the placebo with β-lactams plus fluoroquinolones group in the intention-
to-treat population.
https://doi.org/10.1371/journal.pone.0178022.t003
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[26]. Corticosteroids and macrolides share some anti-inflammatory effects regulating cytokine
release[27]. As regards macrolides, this effect has been observed in in vitro and in vivo studies.
In addition, macrolides have effects on structural cells of the respiratory tract such as endothe-
lial and epithelial cells. In animal studies macrolides show a reduction of histological inflam-
matory signs[28]. These studies have been performed predominantly with Streptococcus
pneumoniae or Mycoplasma pneumoniae models of pneumonia. In an in-vitro study, the
Table 4. Outcomes for the glucocorticosteroids and antibiotic combination treatments using logistic regression or cox proportional hazards mod-
els for the intention-to- treat population.
OR or HR for the
corticosteroid effect*
(Placebo with β-lactams data
were reference values) (95%
CI)
OR or HR for the
antibiotic effect*
(Macrolides data were
reference values) (95%
CI)
OR or HR for the
interaction
effect* (95% CI)
P value for the
corticosteroid
effect#
P value for
the antibiotic
effect#
P value for the
interaction
effect#
Primary
Outcomes
Treatment
failurea
0.37 (0.05 to 2.64) 1.30 (0.31 to 5.51) 1.30 (0.13 to
12.94)
0.320 0.722 0.824
Early
treatment
failure (0–72
h)b
NAc NAc NAc >0.99 >0.99 >0.99
Late treatment
failure (72–120
h)b
NAc 1.40 (0.31 to 6.36) NAc >0.99 0.663 >0.99
Secondary
Outcomes
Time to
clinical
stability, daysd
1.65 (0.64 to 4.27) 0.58 (0.27 to 1.25) 0.63 (0.22 to
1.84)
0.297 0.163 0.403
Length of
hospital stay,
days
0.89 (0.16 to 4.85) 0.42 (0.07 to 2.71) 1.31 (0.10 to
17.58)
0.894 0.364 0.837
Length of ICU
stay, dayse
NAc 0.36 (0.05 to 2.71) NAc 0.959 0.318 0.961
In-hospital
mortality
0.72 (0.10 to 5.44) 0.34 (0.04 to 2.67) 1.48 (0.08 to
26.42)
0.769 0.307 0.791
Abbreviations: CI, confidence interval; HR, hazard ratio; NA; not available; OR, odds ratio.
*Estimate of the OR or HR comparing glucocorticosteroids and antibiotic combination treatments (placebo with β-lactams and macrolides being the
reference groups) derived using either the logistic regression model or the Cox proportional hazards model adjusted for the severity (PSI score), year and
centre of enrolment.
# P values were calculated using either the logistic regression model or the Cox proportional hazards model adjusted for the severity (PSI score), year and
centre of enrolment.
a Defined as the presence of early, late failure or both.
b Several patients had more than 1 criteria of failure.
c Estimation failed due to numerical problem. Because the coefficients did not converge, no further models were fitted.
d Clinical stability was considered to be attained when the following values were achieved for all parameters: temperature of 37.2˚C or lower; heart rate of
100 beats/min or lower; systolic blood pressure of 90 mmHg or higher; and arterial oxygen tension of 60 mmHg or higher when the patient was not receiving
supplemental oxygen. In patients who were receiving home oxygen therapy, stability was considered to be achieved when their oxygen needs were the
same as before admission.
e There were 7 patients in the placebo with β-lactam plus macrolide group, 34 patients in the placebo with β-lactams plus fluoroquinolones group, 6 patients
in the methylprednisolone with β-lactams plus macrolides group, and 36 patients in the placebo with β-lactams plus fluoroquinolones group in the intention-
to-treat population.
https://doi.org/10.1371/journal.pone.0178022.t004
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macrolides showed an improvement in sensitive corticosteroids and higher inhibition in IL-8
levels[29]. In a recent human study, treatment with corticosteroids and macrolides reduced the
level of inflammatory biomarkers such as IL-6 and IL-8 in bronchoalveolar lavage of patients
with non-responding pneumonia[30], also in a recent post-hoc analysis of STEP study the
patients who receiving corticosteroids plus macrolides presented lower re-hospitalisation than
those received β-lactam monotherapy[31]. Macrolides and corticosteroids act on different tar-
gets[32], and their combination could potentiate their immunomodulatory effects. Interestingly,
quinolones have also been associated with immunomodulatory effects during in vitro experi-
ments, ex-vivo investigations, in vivo pre-clinical models and in the clinical setting[33,34].
Treatment failure is common in patients with severe pneumonia, reaching rates of 35% in
high-risk patients (PSI class V)[35,36]. This rate was reduced with corticosteroid treatment to
13% in the original trial[12] and, in this post-hoc analysis, we found an even lower rate in
patients receiving antibiotic treatment with a macrolide and a ß-lactam, along with the gluco-
corticosteroids, where late treatment failure was reduced to 0%. However, because we had few
events, we were unpowered to observe a potential statistically significant interaction between
glucocorticosteroid and antibiotic groups.
Our study included a specific population of patients with community-acquired pneumonia
with high inflammatory response measured by high CRP levels at randomization, and all
patients received β-lactam antibiotic treatment. These criteria allowed us to analyse the target
effect of macrolides and glucocorticosteroids, taking account that different cytokine profiles
were described accordingly to pneumonia aetiology, severity and due to the bactericidal prop-
erties of antimicrobial treatments[26]. There are more than one definition for treatment failure
Table 5. Inflammatory response on day 3 for the glucocorticosteroids and antibiotic combination treatments using ANCOVA models for the inten-
tion-to- treat population.
Placebo with
β-lactams
plus
Macrolides
Group
LS mean
(95% CI)*
Placebo with β-
lactams plus
Fluoroquinolones
Group
LS mean (95% CI)*
Methylprednisolone
with β-lactams plus
Macrolides Group
LS mean (95% CI)*
Methylprednisolone
with β-lactams plus
Fluoroquinolones
Group
LS mean (95% CI)*
P value for the
corticosteroid
effect#
P value for
the
antibiotic
effect#
P value for
the
interaction
effect#
C-reactive
protein at day
3, mg/L
(n = 83)
83.2 (43.3 to
160)
107.2 (61.6 to 186.8) 71.2 (35.2 to 144) 79.4 (47.1 to 133.8) 0.336 0.562 0.774
Procalcitonin
at day 3, ng/L
(n = 85)
1.10 (0.57 to
2.10)
0.89 (0.52 to 1.51) 0.39 (0.20 to 0.75) 0.78 (0.47 to 1.29) 0.016 0.421 0.066
Interleukin-6 at
day 3, pg/dL
(n = 70)
104.3 (50.5 to
215.5)
134.4 (71.4 to 252.9) 32.2 (13.6 to 76.6) 48 (26.3 to 87.9) <0.001 0.374 0.804
Interleukin-8 at
day 3, pg/dL
(n = 69)
78.4 (30.2 to
203.8)
39.9 (17.1 to 92.8) 20.9 (7.4 to 59.1) 31.3 (14.3 to 68.8) 0.028 0.782 0.159
Interleukin-10
at day 3, pg/dL
(n = 79)
4.92 (2.60 to
9.35)
5.52 (3.21 to 9.52) 4.34 (2.20 to 8.57) 2.72 (1.62 to 4.55) 0.076 0.571 0.232
Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; LS, least square.
* LS mean: least square mean for the inflammatory market at day 3 variables in the ANCOVA model.
# P values were calculated using the ANCOVA models adjusted for the inflammatory marker at day 1 (baseline), severity (PSI score), year and centre of
enrolment.
https://doi.org/10.1371/journal.pone.0178022.t005
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for community-acquired pneumonia, and we choose the definition developed in the Neumo-
fail study, which has shown relationship with mortality[36].
Our study has limitations that must be acknowledged. First, the antibiotic choice was not ran-
domized, resulting in heterogeneous groups with differences in baseline characteristics including
severity and admission to ICU. It would appear that attending physicians treat elderly patients
with comorbidities with macrolides and patients admitted to ICU with fluoroquinolones. We
tried to overcome this limitation by adjusting for PSI score, which accounts for age, comorbidities
and severity. Second, the number of patients who received macrolides was small, hindering the
possibility of a fully-adjusted analysis for proper comparison with patients who received fluoro-
quinolones and their interaction with glucocorticosteroids. Third, we did not measure baseline
cortisol, which may be an important marker for measuring the effects of glucocorticosteroids.
In conclusion the glucocorticosteroids and macrolides combination had no statistically sig-
nificant association with main clinical outcomes compared with other combinations in
patients with severe community acquired pneumonia and a high inflammatory response after
taking account potential confounders. We believe this report could be a hypothesis generator
to further RCTs combining glucocorticosteroids with macrolides or fluoroquinolones.
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